Meta-analysis of colistin for the treatment of Acinetobacter baumannii infection

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Chen, Zhijin ^a   Chen, Yu ^c   Fang, Yaogao ^a   Wang, Xiaotian ^a   Chen, Yanqing ^a   Qi, Qingsong ^a   Huang, Fang ^a   Xiao, Xungang ^b  

^a GUANGDONG MEDICAL UNIVERSITY   (China)

^b Chenzhou No1 People's Hospital   (China)

^c HUZHOU UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; COLISTIN;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; COMBINATION DRUG THERAPY; DRUG EFFECTS; HUMAN; LENGTH OF STAY; META ANALYSIS; MICROBIOLOGY; MORTALITY; MULTIDRUG RESISTANCE; TREATMENT OUTCOME;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; ANTI-BACTERIAL AGENTS; COLISTIN; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG THERAPY, COMBINATION; HUMANS; LENGTH OF STAY; TREATMENT OUTCOME;

EID: 84948146553     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep17091     Document Type: Article

References (43)

1. Towner, K. Acinetobacter: an old friend, but a new enemy. J Hosp Infect 73, 355-363 (2009).
2. Dijkshoorn, L. & Nemec, A. The diversity of the genus Acinetobacter. Acinetobacter, Molecular Biology 2, 1-34 (2008).
3. Bergogne-Berezin, E. & Towner, K. Acinetobacter spp. as nosocomial pathogens: microbiological, clinical, and epidemiological features. Clinical microbiology reviews 9, 148 (1996).
4. Sunenshine, R. H. et al. Multidrug-resistant Acinetobacter infection mortality rate and length of hospitalization. Emerg Infect Dis 13, 97-103 (2007).
5. Gordon, N. C. & Wareham, D. W. Multidrug-resistant Acinetobacter baumannii: mechanisms of virulence and resistance. Int J Antimicrob Agents 35, 219-226 (2010).
6. Tasina, E., Haidich, A. B., Kokkali, S. & Arvanitidou, M. Efficacy and safety of tigecycline for the treatment of infectious diseases: a meta-analysis. Lancet Infect Dis 11, 834-844 (2011).
7. Falagas, M. E. & Kasiakou, S. K. Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. Clin Infect Dis 40, 1333-1341 (2005).
8. Hancock, R. E. Peptide antibiotics. Lancet 349, 418-422 (1997).
9. Oleksiuk, L. M. et al. In Vitro Responses of Acinetobacter baumannii to Two-and Three-Drug Combinations following Exposure to Colistin and Doripenem. Antimicrob Agents Ch 58, 1195-1199 (2014).
10. Society, A. T. Infectious Diseases Society of AmericaAmerican Thoracic Society; Infectious Diseases Society of America Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 1714, 388-416 (2005).
11. Li, J. et al. Heteroresistance to colistin in multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Ch 50, 2946-2950 (2006).
12. Nakwan, N. et al. Safety in treatment of ventilator-associated pneumonia due to extensive drug-resistant Acinetobacter baumannii with aerosolized colistin in neonates: A preliminary report. Pediatr Pulm 46, 60-66 (2011).
13. Betrosian, A. P., Frantzeskaki, F., Xanthaki, A. & Douzinas, E. E. Efficacy and safety of high-dose ampicillin/sulbactam vs. colistin as monotherapy for the treatment of multidrug resistant Acinetobacter baumannii ventilator-associated pneumonia. J Infection 56, 432-436 (2008).
14. Gounden, R., Bamford, C., van Zyl-Smit,R., Cohen, K. & Maartens, G. Safety and effectiveness of colistin compared with tobramycin for multi-drug resistant Acinetobacter baumannii infections. BMC Infect Dis 9, 26 (2009).
15. Garnacho-Montero, J. et al. Treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia (VAP) with intravenous colistin: a comparison with imipenem-susceptible VAP. Clin Infect Dis 36, 1111-1118 (2003).
16. Kwon, S. H., Ahn, H. L., Han, O. Y. & La, H. O. Efficacy and Safety Profile Comparison of Colistin and Tigecycline on the Extensively Drug Resistant Acinetobacter baumannii. Biol Pharm Bull 37, 340-346 (2014).
17. Chuang, Y.-C. et al. Effectiveness of tigecycline-based versus colistin-based therapy for treatment of pneumonia caused by multidrug-resistant Acinetobacter baumannii in a critical setting: a matched cohort analysis. BMC Infect Dis 14, 102 (2014).
18. Aydemir, H. et al. Colistin vs. the combination of colistin and rifampicin for the treatment of carbapenem-resistant Acinetobacter baumannii ventilator-associated pneumonia. Epidemiol Infect 141, 1214-1222 (2013).
19. Batirel, A. et al. Comparison of colistin-carbapenem, colistin-sulbactam, and colistin plus other antibacterial agents for the treatment of extremely drug-resistant Acinetobacter baumannii bloodstream infections. Eur J Clin Microbiol 33, 1311-1322 (2014).
20. Simsek, F. et al. Colistin against colistin-only-susceptible Acinetobacter baumannii-related infections: Monotherapy or combination therapy? Indian J Med Microbiol 30, 448-452 (2012).
21. Kalin, G., Alp, E., Akin, A., Coskun, R. & Doganay, M. Comparison of colistin and colistin/sulbactam for the treatment of multidrug resistant Acinetobacter baumannii ventilator-associated pneumonia. Infection 42, 37-42 (2014).
22. Jang, H. J. et al. The comparative efficacy of colistin monotherapy and combination therapy based on in vitro antimicrobial synergy in ventilator-associated pneumonia caused by multi-drug resistant Acinetobacter baumannii. Tuberculosis and Respiratory Diseases 67, 212-220 (2009).
23. Durante-Mangoni, E. et al. Colistin and rifampicin compared with colistin alone for the treatment of serious infections due to extensively drug-resistant Acinetobacter baumannii: a multicenter, randomized clinical trial. Clin Infect Dis 57, 349-358 (2013).
24. Boucher, H. W. et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 48, 1-12 (2009).
25. Azzopardi, E. A., Ferguson, E. L. & Thomas, D. W. Colistin past and future: a bibliographic analysis. J Crit Care 28, 219 (2013).
26. Wolinsky, E. & Hines, J. D. Neurotoxic and nephrotoxic effects of colistin in patients with renal disease. New Engl J Med 266, 759-762 (1962).
27. Li, J. et al. Heteroresistance to colistin in multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Ch 50, 2946-2950 (2006).
28. Petrosillo, N. et al. Combined colistin and rifampicin therapy for carbapenem-resistant Acinetobacter baumannii infections: clinical outcome and adverse events. Clin Microbiol Infec 11, 682-683 (2005).
29. Liu, Q., Li, W., Feng, Y. & Tao, C. Efficacy and Safety of Polymyxins for the Treatment of Acinectobacter baumannii Infection: A Systematic Review and Meta-Analysis. PLoS One 9, e98091 (2014).
30. Petrosillo, N., Ioannidou, E. & Falagas, M. Colistin monotherapy vs. combination therapy: evidence from microbiological, animal and clinical studies. Clin Microbiol Infec 14, 816-827 (2008).
31. Pogue, J. M. & Kaye, K. S. Is there really no benefit to combination therapy with colistin? Expert Rev Anti Infect Ther 11, 881-884, doi: 10.1586/14787210.2013.827881 (2013).
32. Bassetti, M. et al. Colistin and rifampicin in the treatment of multidrug-resistant Acinetobacter baumannii infections. J Antimicrob Chemother 61, 417-420 (2008).
33. Cai, Y., Chai, D., Wang, R., Liang, B. & Bai, N. Colistin resistance of Acinetobacter baumannii: clinical reports, mechanisms and antimicrobial strategies. J Antimicrob Chemother 67, 1607-1615 (2012).
34. Lee, H. J. et al. Synergistic activity of colistin and rifampin combination against multidrug-resistant Acinetobacter baumannii in an in vitro pharmacokinetic/pharmacodynamic model. Antimicrob Agents Ch 57, 3738-3745 (2013).
35. Mutlu Yilmaz, E. et al. Efficacy of tigecycline/colistin combination in a pneumonia model caused by extensively drug-resistant Acinetobacter baumannii. Int J Antimicrob Agents 40, 332-336 (2012).
36. Garnacho-Montero, J. et al. Clinical efficacy and safety of the combination of colistin plus vancomycin for the treatment of severe infections caused by carbapenem-resistant Acinetobacter baumannii. Chemotherapy 59, 225-231 (2013).
37. Khawcharoenporn, T., Apisarnthanarak, A. & Mundy, L. M. Intrathecal colistin for drug-resistant Acinetobacter baumannii central nervous system infection: a case series and systematic review. Clin Microbiol Infec 16, 888-894 (2010).
38. Kang, C. H. et al. Colistin inhalation monotherapy for ventilator-associated pneumonia of Acinetobacter baumannii in prematurity. Pediatr Pulm 49, 381-388 (2013).
39. Hawley, J. S., Murray, C. K. & Jorgensen, J. H. Development of colistin-dependent Acinetobacter baumannii-Acinetobacter calcoaceticus complex. Antimicrob Agents Ch 51, 4529-4530 (2007).
40. Magiorakos, A. P. et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infec 18, 268-281 (2012).
41. Woolf, B. On estimating the relation between blood group and disease. Ann Hum Genet 19, 251-253 (1955).
42. Mantel, N. & Haenszel, W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22, 719-748 (1959).
43. DerSimonian, R. & Laird, N. Meta-analysis in clinical trials. Control Clin Trials 7, 177-188 (1986).